NAMI
ALNY icon

Nomura Asset Management International’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nomura Asset Management International’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.4M Buy
300,193
+41,288
+16% +$12.5M 0.14% 184
2026
Q1 		$85.7M Sell
258,905
-52,852
-17% -$18M 0.15% 185
2025
Q4 		$124M Buy
+311,757
New +$138M 0.19% 124

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nomura Asset Management International's ALNY Position: Q2 2026 in Review

Nomura Asset Management International increased its Alnylam Pharmaceuticals (ALNY) stake by 16% in Q2 2026, buying an estimated $12.5M and bringing the position to 300,193 shares worth $90.4M. The position accounts for 0.14% of the portfolio, ranked #184.

Nomura Asset Management International first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $124M in Q4 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Nomura Asset Management International held 300,193 shares of Alnylam Pharmaceuticals worth $90.4M as of Q2 2026.
  • Nomura Asset Management International bought 41,288 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $12.5M.
  • Alnylam Pharmaceuticals made up 0.14% of Nomura Asset Management International's portfolio in Q2 2026, its #184 holding.
  • Nomura Asset Management International first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Nomura Asset Management International's Alnylam Pharmaceuticals position peaked at $124M in Q4 2025.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Nomura Asset Management International's 13F filing for Q2 2026, filed 14 Aug 2026.